methylphenidate and Body Weight

methylphenidate has been researched along with Body Weight in 124 studies

Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.
methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.
methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.

Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.

Research

Studies (124)

Authors

Clinical Trials (6)

Trial Overview

Trial Outcomes

ADHD Symptoms- Parent Rated

sum of score on 10 item IOWA Conners with range from 0 to 30 and higher values indicating more symptoms. Collected at end point or last assessment point. (NCT01109849)
Timeframe: at month 30 or last collected assessment point

ADHD Symptoms- Teacher Rated

sum of items on 10 item IOWA Conners with range from 0-30 and larger values indicating greater symptoms. Collected at endpoint or last assessment point. (NCT01109849)
Timeframe: month 30 or last assessment point

Change in BMI z Score by Actual Medication Usage

measures change in BMI z score from baseline to last assessment with participants grouped based on actual medication usage versus randomly assigned group since participants were allowed to cross treatment arms after 6 months and not all participants assigned to medication used it consistently. The rarely med group (n=44) used med <12.5% of the study duration (with most using not at all). The consistent med group (N=38 used med for at least 87.5% of their time in the study with most using the entire time). The inconsistent med group (N=111, 27.5% used medication 45% of the time in the study. The other 37 participants did not have one year of growth data so were excluded from this analysis. Z scores used to account for differences in age and gender between groups. Higher values represent a larger BMI (NCT01109849)
Timeframe: baseline to month 30 or last assessment point

Change in BMI z Score During Weight Recovery Period (Second Randomization) Based on Actual Usage

"difference in height z score from entry into weight recovery phase to exit from that phase (exact duration varied by participant). Randomization could not occur before month 6 (so max of 24 month duration) but could start as late as month 29 (equaling a 1 month duration) based on the pattern of zBMI change. In this post hoc analysis we grouped participants by what they did (caloric supplementation, drug holiday or monitoring) not what they were randomly assigned to. The most common change was from drug holiday to monitoring for participants who were not using medication on weekends before assignment to drug holiday (family stopped weekend med by own accord prior to 2nd randomization) so assignment to drug holiday did not alter actual frequency of use as was designed to.Therefore they were reclassified as monitoring as frequency of med use did not change.~Z score used to account for differences in age and gender between groups. Higher values reflect greater incremental BMI increase." (NCT01109849)
Timeframe: between 1 month and 24 months

Change in Height z Score by Actual Medication Usage

measures change in height z score from baseline to last assessment with participants grouped based on actual medication usage versus randomly assigned group since participants were allowed to cross treatment arms after 6 months and not all participants assigned to medication used it consistently. The rarely med group (n=44) used med <12.5% of the study duration (with most using not at all). The consistent med group (N=38 used) med for at least 87.5% of their time in the study with most using the entire time. The inconsistent med group (N=111), used medication between 12.5 to 87.5 of the time (mean time on med was 45% of the time in the study) The other 37 participants did not have one year of growth data so were excluded from this analysis. Z scores used to account for differences in age and gender between groups. More negative values reflecting a smaller incremental height gain. (NCT01109849)
Timeframe: baseline to month 30 or last assessment point

Change in Height z Score During Weight Recovery Phase (Second Randomization)

"difference in height z score from entry into weight recovery phase to exit from weight recovery phase (exact duration varied by participant). Randomization could not occur before month 6 (equaling a 24 month duration) but could start as late as month 29 (equaling a 1 month duration) of treatment based on the pattern of zBMI change by the individual participant.~Z scores used to account for differences in age and gender. More negative values reflecting less incremental height gain." (NCT01109849)
Timeframe: between 1 month and 24 months

Change in Weight z Score by Actual Medication Usage

measures change in weight z score from baseline to last assessment with participants grouped based on actual medication usage versus randomly assigned group since participants were allowed to cross treatment arms after 6 months and not all participants assigned to medication used it consistently. The rarely med group (n=44) used med <12.5% of the study duration (with most using not at all). The consistent med group (N=38 used med for at least 87.5% of their time in the study with most using the entire time). The inconsistent med group (N=111, 27.5% used medication 45% of the time in the study. The other 37 participants did not have one year of growth data so were excluded from this analysis. Z scores used to account for differences in age and gender between groups. Higher values represent a greater incremental weight gain. (NCT01109849)
Timeframe: baseline to month 30 or last assessment point

Change in Weight z Score During Weight Recovery Phase (Second Randomization)

"difference in weight z score from entry into weight recovery phase to exit from weight recovery phase (exact duration varied by participant). Randomization could not occur before month 6 (equaling a 24 month duration) but could start as late as month 29 (equaling a 1 month duration) of treatment based on the pattern of zBMI change by the individual participant.~Z scores used to account for differences in age and gender. Larger values reflect a greater incremental weight gain." (NCT01109849)
Timeframe: 1 to 24 months duration

Change in Weight z Score During Weight Recovery Phase (Second Randomization) Based on Actual Usage

"difference in height z score from entry into weight recovery phase to exit from that phase (exact duration varied by participant). Randomization could not occur before month 6 (so max of 24 month duration) but could start as late as month 29 (equaling a 1 month duration) based on the pattern of zBMI change. In this post hoc analysis we grouped participants by what they did (caloric supplementation, drug holiday or monitoring) not what they were randomly assigned to. The most common change was from drug holiday to monitoring for participants who were not using medication on weekends before assignment to drug holiday (family stopped weekend med by own accord prior to 2nd randomization) so assignment to drug holiday did not alter actual frequency of use as was designed to.Therefore they were reclassified as monitoring as frequency of med use did not change.~Z score used to account for differences in age and gender between groups. Higher values reflect greater incremental weight gain." (NCT01109849)
Timeframe: between 1 month and 24 months

Change in zBody Mass Index (BMI)

BMI will be calculated at endpoint (month 30). Difference between baseline and endpoint (month 30 or last assessment point if did not finish study). Measured as a zscore with more negative units reflecting less BMI gain. Z units used to account for differences between groups in gender and age with both impact BMI at a fixed time. (NCT01109849)
Timeframe: baseline to month 30 or last assessment point

Change in Zscore for BMI During Weight Recovery Phase (Second Randomization)

"difference in BMI z score from entry into weight recovery phase to exit from weight recovery phase (exact duration varied by participant). Randomization could not occur before month 6 (equaling a 24 month duration) but could start as late as month 29 (equaling a 1 month duration) of treatment based on the pattern of zBMI change by the individual participant.~Z scores used to account for differences in age and gender. Larger values reflecting a greater incremental BMI gain." (NCT01109849)
Timeframe: between 1 month and 24 months

Change Score for z Weight

difference between baseline and endpoint (month 30 or last assessment point if did not finish study). Measured as a zscore with more negative units reflecting lesser weight gain. Z units used to account for differences between groups in gender and age with both impact weight at a fixed time. (NCT01109849)
Timeframe: baseline to month 30 or to last assessment point

Change Score for Z-height Baseline to Endpoint

"The primary endpoint will be change in z-height at month 30 which is study endpoint.~Measured as a zscore with more negative units reflecting smaller incremental height gain. Z units used to account for differences between groups in gender and age with both impact height at a fixed time." (NCT01109849)
Timeframe: month 30 or last assessment point

Change Score for Zheight Months 0 to 6

"in addition to the primary outcome of height at month 30, change in z-height from baseline to study month 6 post is also reported. Subjects who were still moderately impaired after 6 months in their initial treatment arm were allowed to cross over and receive the treatments in the other arm so prior to month 6 no participants randomized to behavior arm were prescribed study medication.~This outcome includes all participants with 2+ growth assessments from the behavior therapy and ER stimulant arms. Doesn't include adaptive randomization arms (drug holiday, cal supplement, monitoring) as they didn't exist until 2nd randomization which did not occur until after this assessment period was over.~Height converted to z score to account for differences in age and gender. More negative values reflecting smaller incremental height gain.~If participant dropped out prior to month 6, then the last assessment point was used." (NCT01109849)
Timeframe: baseline to month 6

Difference in Height z Score During Weight Recovery Phase (Second Randomization) by Actual Usage

"difference in height z score from entry into weight recovery phase to exit from that phase (exact duration varied by participant). Randomization could not occur before month 6 (so max of 24 month duration) but could start as late as month 29 (equaling a 1 month duration) based on the pattern of zBMI change. In this post hoc analysis we grouped participants by what they did (caloric supplementation, drug holiday or monitoring) not what they were randomly assigned to. The most common change was from drug holiday to monitoring for participants who were not using medication on weekends before assignment to drug holiday (family stopped weekend med by own accord prior to 2nd randomization) so assignment to drug holiday did not alter actual frequency of use as was designed to.Therefore they were reclassified as monitoring as frequency of med use did not change.~Z score used to account for differences in age and gender between groups. Larger values reflect greater height change." (NCT01109849)
Timeframe: between 1 month and 24 months

Medication Adherence

% of study days that study ADHD medication was taken when prescribed to be taken; behavior group could be prescribed medication if moderately impaired still after month 6. Once prescribed, all medication was prescribed to be taken 7 days a week except for in the drug holiday weight recovery arm. (NCT01109849)
Timeframe: denominator is number of days in study for which study med was prescribed

Number of Behavior Therapy Sessions

Raw number of behavior therapy sessions attended; participants could cross over to other treatment arm if moderately impaired after 6 months in initial randomly assigned arm (NCT01109849)
Timeframe: months 0 through 30

Treatment Adherence for Caloric Supplement

percent of days caloric supplement were taken versus prescribed in caloric supplement arm (NCT01109849)
Timeframe: from entry to exit of caloric supplement arm

Change From Baseline ADHD Rating Scale-IV Scores at 8 Weeks

"Attendtion-deficit hyperactivity disorder (ADHD) Rating Scale-IV is the sum of 18 questions, ranging from 0 (no symptoms) to 54 (worst possible symptoms).~Change from baseline ADHD Rating Scale-IV scores at 8 weeks was calculated as baseline minus 8 weeks." (NCT01912352)
Timeframe: baseline and 8 weeks

Clinical Global Impression-Improvement Scale at 8 Weeks

"Clinical Global Impression-Improvement (CGI-I) scale is a one-item measure evaluating the change from the initiation of treatment on a seven-point scale: Compared to the patient's condition at baseline [prior to medication initiation], this patient's condition is: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment.~Clinical Global Impression-Improvement was measured at 8 weeks." (NCT01912352)
Timeframe: baseline and 8 weeks

Diagnostic and Statistical Manual-IV(DSM-IV) ADHD Rating Scale

A Generalized Estimating Equations(GEE)model which included treatment group, week, site, and treatment by week and site by week interaction effects was used to compare the groups on the DSM-IV ADHD total severity score (18 domains score at severity levels of 0[none]-3[severe]; maximum score 54) as measured at screening/baseline and study weeks 1-4 using the the interviewer-administered DSM-IV checklist and by the severity portion of the National Institute of Mental Health Clinical Global Impression (CGI) scale to rate the severity of the participant's ADHD symptoms. A single severity score ranging from 1 to 7 is yielded by the CGI severity scale. (NCT00253747)
Timeframe: Baseline and Study weeks 1,4,7,9,11

Point-prevalence Abstinence

A logistic regression including site and treatment group will be used to model rates of achieving point prevalence abstinence as assessed at the final visit of the O-MPH/P-Stnd Smoking Tx phase. Point prevalence abstinence was defined as not smoking in the previous seven days based on self-report using the TLFB method and confirmed with a Carbon Monoxide (CO) level <8 ppm. (NCT00253747)
Timeframe: Week 11

Prolonged Abstinence

"The smoking quit date was considered the first day of the O-MPH/P-Stnd Smoking Tx phase, which lasted for 6 weeks or more precisely 42 days (i.e., approximately weeks 5-10). The grace period was the first two weeks (i.e., days 1-14) with the remaining four weeks (days 15-42) comprising the period in which the participant must not meet criteria for treatment failure in order to be scored as obtaining prolonged abstinence. Self-report of cigarette use was assessed using a time-line follow-back (TLFB) assessment using carbon monoxide (CO)levels to correct self-reported smoking days. Smoking days were determined by starting with self-reported smoking and non-smoking days and using CO levels measured at weekly visits to modify the self-reports." (NCT00253747)
Timeframe: Weeks 7-10

Reviews

7 reviews available for methylphenidate and Body Weight

Trials

23 trials available for methylphenidate and Body Weight

Other Studies

94 other studies available for methylphenidate and Body Weight